| Q36663603 | Acute myeloid leukaemia |
| Q46701464 | Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication |
| Q30277009 | Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia |
| Q35811893 | Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile |
| Q36530726 | Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type |
| Q37842488 | Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations |
| Q38168893 | Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. |
| Q48568744 | Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| Q49446408 | Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: does age really matter? |
| Q37559330 | Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification |
| Q54208508 | Allogeneic transplant for FLT3-ITD+ AML: room for improvement. |
| Q36498807 | Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation |
| Q38757020 | Cerebellar granulocytic sarcoma: a case report |
| Q33572303 | Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial |
| Q35848876 | Clinical implications of FLT3 mutations in pediatric AML. |
| Q37363129 | Clinical implications of molecular genetic aberrations in acute myeloid leukemia |
| Q37323006 | Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation |
| Q28301344 | Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review |
| Q35615901 | Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? |
| Q39601810 | Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio |
| Q36390379 | Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. |
| Q37089717 | Cooperating gene mutations in acute myeloid leukemia: a review of the literature. |
| Q54566271 | Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. |
| Q36931642 | Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors |
| Q39674948 | Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis |
| Q36817144 | Early gene expression of acute myeloid leukemia in response to chemotherapy |
| Q79906767 | East and west together. Abstracts of the Leukemia and Lymphoma Meeting. Dubrovnik, Croatia. September 15-19, 2007 |
| Q52672101 | Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. |
| Q64250050 | Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia |
| Q84615573 | FLT3 Mutations at Diagnosis and Relapse in Acute Myeloid Leukemia: Cytogenetic and Pathologic Correlations, Including Cuplike Blast Morphology |
| Q38200564 | FLT3 inhibitors in AML: are we there yet? |
| Q91312491 | FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients |
| Q36484100 | FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML |
| Q27028163 | FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? |
| Q28289859 | FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations |
| Q35127958 | FLT3/ITD AML and the law of unintended consequences |
| Q33737486 | Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). |
| Q34595162 | Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status |
| Q53488661 | Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics. |
| Q38044773 | Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? |
| Q33879678 | High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia |
| Q37623389 | How I treat FLT3-mutated AML. |
| Q39932813 | Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? |
| Q39040937 | Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. |
| Q90911358 | Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation |
| Q42361918 | Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia |
| Q34620761 | Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. |
| Q39570532 | Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007. |
| Q36862461 | Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse |
| Q38989349 | Inhibition of FLT3 in AML: a focus on sorafenib |
| Q37442649 | Interactive diagnostics in the indication to allogeneic SCT in AML. |
| Q38272140 | Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review |
| Q43986169 | Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study |
| Q37810104 | Lestaurtinib: a multi-targeted FLT3 inhibitor |
| Q37117735 | Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia |
| Q34409299 | Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort |
| Q104111298 | Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia |
| Q54275690 | Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete re |
| Q37812861 | Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications |
| Q37236994 | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| Q51753853 | Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution. |
| Q53594087 | Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. |
| Q39252132 | Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. |
| Q33774504 | Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis |
| Q38967853 | Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia |
| Q34620695 | Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia |
| Q38183943 | Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. |
| Q37954583 | Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics |
| Q54551190 | Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. |
| Q35215042 | Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report |
| Q36929806 | Progress in the treatment of acute myeloid leukemia |
| Q40396505 | Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation |
| Q39977455 | Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. |
| Q46721176 | Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. |
| Q37842861 | Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution |
| Q38204207 | Should persons with acute myeloid leukemia have a transplant in first remission? |
| Q37316816 | Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation |
| Q24338964 | Structural and functional alterations of FLT3 in acute myeloid leukemia |
| Q37257308 | Targeting FLT3 for the treatment of leukemia |
| Q38251339 | Targeting FLT3 to treat leukemia |
| Q38040708 | The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach |
| Q92757496 | The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia |
| Q34555386 | The Future of Targeting FLT3 Activation in AML. |
| Q37671778 | The challenge of risk stratification in acute myeloid leukemia with normal karyotype |
| Q21284742 | The epigenetic landscape of acute myeloid leukemia |
| Q50216333 | The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients |
| Q48255430 | The importance of FLT3 mutational analysis in acute myeloid leukemia. |
| Q37738548 | The role of molecular tests in acute myelogenous leukemia treatment decisions |
| Q38913785 | Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation |
| Q34636735 | Treatment of FLT3-ITD acute myeloid leukemia. |
| Q47125391 | UCB HCT in FLT3+ AML. |
| Q42391575 | Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. |
| Q35018514 | Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling |
| Q53402031 | Who should be transplanted in first remission of acute myeloid leukaemia? |
| Q89933297 | [The clinical and prognostic significance of acute myeloid leukemia with FLT3-ITD] |